Samuel Bates Martin - Nov 15, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Stock symbol
CLDX
Transactions as of
Nov 15, 2021
Transactions value $
-$374,155
Form type
4
Date filed
11/17/2021, 03:02 PM
Previous filing
Aug 12, 2021
Next filing
Dec 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $29.3K +3.25K +11.06% $9.02 32.6K Nov 15, 2021 Direct
transaction CLDX Common Stock Options Exercise $10.4K +3.75K +11.49% $2.78* 36.4K Nov 15, 2021 Direct
transaction CLDX Common Stock Sale -$327K -7.45K -20.48% $43.92 28.9K Nov 15, 2021 Direct F1, F2
transaction CLDX Common Stock Sale -$86.6K -2.05K -7.08% $42.27 26.9K Nov 15, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3.25K -20.27% $0.00 12.8K Nov 15, 2021 Common Stock 3.25K $9.02 Direct F4
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3.75K -11.75% $0.00 28.2K Nov 15, 2021 Common Stock 3.75K $2.78 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.24 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.11 to $42.77 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.